Skip to content

Mechanism research of the hemorrheologic abnormality in patients with type 2 diabetes mellitus

Mechanism research of the hemorrheologic abnormality in patients with type 2 diabetes mellitus

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800017123
Enrollment
Unknown
Registered
2018-07-12
Start date
2018-08-01
Completion date
Unknown
Last updated
2018-07-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes mellitus

Interventions

Sponsors

Shanghai Ninth People's Hospital, School of Medicine, Shanghai Jiao Tong University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. According to the WHO 1999 diagnose standard for T2DM: fasting plasma glucose = 7.0 mmol/l ,or 2-hr glucose =11.1mmol/l with a glucose tolerance test, or random blood glucose = 11.1 mmol/l in association with typical symptoms; 2. All enrolled patients will volunteer to participate and sign the subject's informed consent.

Exclusion criteria

Exclusion criteria: 1. Acute complications of T2DM including diabetic ketoacidosis, diabetic hyperosmotic coma, etc.; 2. During pregnancy and lactation; 3. Patients in stress state with acute diseases, for example myocardial infarction, severe infection, trauma, etc. within 3 months; 4. Diabetic patients with severe cerebral, renal, cardiac, pulmonary, hepatic and neuromuscular diseases; 5. Histories of severe radiation exposure, vitamin B12 deficiency and neuropathy caused by drug or alcohol; 6. Anaemia or with other hematological diseases; 7. History of cancer.

Design outcomes

Primary

MeasureTime frame
blood viscosity;high shear reduction viscosity, low shear reduction viscosity;Erythrocyte Rigidity Index;Erythrocyte Deformation Index;anti-peroxidase activity of erythrocyte;(Ca2+) i of erythrocyte;ROS of erythrocyte;H2S;plasma viscosity;neural electrophysiological study;blood glucose;blood lipid;blood routine test;urine routine test;stool routine test;blood insulin;Blood c-peptide;Echocardiography;quantitative test of 24h urinary protein;electrocardiography;chest radiography;(Cl) i of erythrocyte;(NO) i of erythrocyte;[superoxide aninon]i of erythrocyte;the levels of spectrin cytoskeleton and its phosphorylation in erythrocytes;parathyroid hormone;sex hormones;blood HbA1c;

Secondary

MeasureTime frame
myocardial enzymes;blood islet cell antibody;blood electrolytes;hepatorenal function;Blood troponin I;C-reactive protein;erythrocyte sedimentation rate;ocular fundus examination;urine protein/creatinine;thyroid immune antibodies;Thyroid stimulating hormone;thyroid hormones;

Countries

China

Contacts

Public ContactLi-Zhen Yang
dryanginsh@yahoo.com+86 15618690375

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026